Anti-DDAH2 Polyclonal Antibody for WB, IHC-P, IF/ICC, ELISA - O95865

Core Product Specifications and Parameters

Biological Background: DDAH2 Function and Localization

• DDAH2 is a putative hydrolase that does not hydrolyze asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor, distinguishing it from the active DDAH1 enzyme. Related references: PMID:21493890, PMID:37296100

• In endothelial cells, DDAH2 induces vascular endothelial growth factor (VEGF) expression through PKA-mediated phosphorylation of transcription factor SP1, independent of nitric oxide and NOS activity.

• DDAH2 enhances pancreatic insulin secretion by up-regulating secretagogin/SCGN, an insulin vesicle docking protein, via SP1-mediated transcriptional activation.

• Upon viral infection, DDAH2 relocates to mitochondria where it promotes mitochondrial fission by activating DNM1L, inhibiting the MAVS-mediated innate immune response. Related references: PMID:33850055

• Subcellular localization includes the cytoplasm and mitochondria, consistent with its roles in signal transduction and mitochondrial dynamics.

• DDAH2 is widely expressed in tissues, with highest levels in heart, placenta, lung, liver, skeletal muscle, kidney, and pancreas, and very low expression in brain.

• Keywords associated with DDAH2 include hydrolase activity (predicted), mitochondrial and cytoplasmic localization, and proteomics identification, reflecting its emerging non-enzymatic functions.

Experimental Guidance and Technical Tips

• The immunogen corresponds to the full-length human DDAH2 protein (residues 1–285), suggesting potential detection of endogenous DDAH2 across species based on cross-reactivity data (human, mouse, rat).
• For Western blot, consider using positive control lysates from tissues with high DDAH2 expression (e.g., heart or placenta) and validate the band size at approximately 30 kDa.
• In immunohistochemistry (IHC-P), optimize antigen retrieval conditions and include isotype controls to minimize non-specific staining.
• For immunofluorescence (IF/ICC), fixation and permeabilization protocols may require optimization to preserve epitope accessibility and cellular morphology.
• ELISA applications can be used for quantitative detection; for sandwich ELISA, pairing with a matched detection antibody is advised.
• Always validate the antibody in the specific experimental context and sample system, as performance can vary with assay conditions.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio provides diagnostic manufacturers, laboratories, and research institutes with reliable IVD raw materials for DDAH2-related research, including validated antibody pairs, optimized monoclonal/polyclonal antibodies, bulk ancillary reagents, and customized sourcing solutions for rare targets. Partner with us to streamline your assay development from concept to clinic, leveraging our comprehensive supply chain and technical support for vascular biology, metabolism, and immunology applications.